GLP-1 & Incretins News
Every article we’ve published on GLP-1 & Incretins, newest first — 26 in total. Each one is sourced to primary regulatory, trial, or peer-reviewed documents and links back to the original.
GLP-1 After Bariatric Surgery: Phase 4 Trial Now Recruiting
Two academic randomized trials are now attacking the same unanswered question: what should happen to GLP-1 after bariatric surgery. One is recruiting 150 patients in Missouri; the other, GRABS, has just published its rationale, design and baseline characteristics. For anyone tracking a GLP-1 protocol through a planned surgery, this is the evidence that does not yet exist.
NNC0662-0419 Phase 2 Trial Compares Novo Drug to Semaglutide
A newly posted NNC0662-0419 phase 2 trial record shows Novo Nordisk testing an experimental blood-sugar medicine head-to-head against semaglutide in 270 people with type 2 diabetes. For anyone following what comes after the current generation of GLP-1 drugs, the choice of comparator is the detail worth noting.
Cagrilintide Bone Density Trial Opens With Semaglutide Comparator
A newly posted cagrilintide bone density trial puts an amylin analogue head-to-head with semaglutide and with the CagriSema combination, and its stated purpose is bone health rather than weight. For anyone tracking a GLP-1 or incretin protocol, it is a signal that skeletal outcomes are moving from footnote to primary question.
Tirzepatide Binge Eating Disorder Trial Opens at Johns Hopkins
A Phase 2 tirzepatide binge eating disorder trial run by Johns Hopkins University is listed as recruiting on ClinicalTrials.gov, with 105 planned participants and a three-arm design that pits the dual incretin drug against both placebo and an established binge-eating medication. It is one of the first registered attempts to test whether an incretin therapy does anything for binge eating that is separable from weight loss.
Semaglutide Smoking Cessation Trial Opens Recruiting in Diabetes
A new semaglutide smoking cessation trial listed on ClinicalTrials.gov is recruiting 100 participants with diabetes to test the GLP-1 receptor agonist as an add-on to nicotine replacement therapy. It is one of several studies registered or published this week pushing incretin drugs well beyond weight and glucose control.
Enobosarm GLP-1 Trial: 239-Patient Muscle Study Closes Enrollment
A ClinicalTrials.gov update dated September 4, 2026 shows the enobosarm GLP-1 trial has finished enrolling 239 participants and moved into its active, non-recruiting phase. It is one of the clearest signals yet that drug development around incretin therapy has shifted from how much weight comes off to what tissue comes off with it.
Stopping and Restarting Tirzepatide Gets Its Own Clinical Trial
Registry records updated in early September 2026 show researchers are now studying stopping and restarting tirzepatide as a deliberate, measured event rather than an accident of insurance or supply. A separate Phase 3a trial is testing early semaglutide re-initiation after bariatric surgery in adolescents.
CagriSema vs Tirzepatide Trial Completes in Type 2 Diabetes
A phase 3 CagriSema vs tirzepatide trial in more than a thousand adults with type 2 diabetes has moved to completed status on the federal trial registry, setting up the first direct comparison between Novo Nordisk's investigational amylin-GLP-1 combination and Eli Lilly's approved dual agonist. Two separate phase 3 trials of cagrilintide on its own also appeared in the same registry update.
Semaglutide Lifespan Mice Study: What the Nature Paper Actually Found
A semaglutide lifespan mice study published in Nature reports that older female mice given the GLP-1 drug lived longer and scored better on health measures than untreated animals. The National Institutes of Health says the effect went beyond what calorie restriction alone produced — a claim that will shape how the drug class is discussed for years, and one that arrives the same week European regulators fined news outlets for over-enthusiastic GLP-1 coverage.
FDA Unapproved GLP-1 Drugs Alert: What the Agency Is Warning About
The FDA refreshed its standing alert on unapproved GLP-1 drugs used for weight loss on September 1, 2026, restating why products sourced outside the approved supply chain carry risks the agency cannot vouch for. For anyone tracking a semaglutide or tirzepatide protocol, the practical question is where the product came from and what is actually on the label.
Weight Regain After Stopping Semaglutide Mapped in New Meta-Analysis
A reconstructed aggregate-data meta-analysis published in Endocrinology, Diabetes & Metabolism models weight regain after stopping semaglutide or tirzepatide, and it landed the same week as a separate analysis of glycaemic changes after semaglutide discontinuation in type 1 diabetes. Together they sharpen a question that matters to anyone on a GLP-1 protocol: what happens when the injections stop.
CagriSema Phase 3 Trials Expand Into Children and a New Dose Comparison
ClinicalTrials.gov records reviewed on August 31, 2026 show the CagriSema phase 3 trials program has widened to include adolescents and a head-to-head comparison of two CagriSema dose levels against semaglutide alone. For anyone already tracking a semaglutide protocol, this is the clearest signal yet of what the next generation of injectable obesity medicines is being tested to do.
Retatrutide Diabetic Ketoacidosis Case Report Involves Online Source
A single-patient report newly indexed in PubMed describes retatrutide diabetic ketoacidosis risk in a type 1 diabetes patient who bought the investigational drug online while also fighting a bacterial gut infection. It is the kind of case that surfaces when an unapproved molecule circulates faster than its clinical evidence.
Semaglutide heart effects: new cardiac CT and tissue studies
A cluster of new peer-reviewed publications shifts attention from weight and glucose toward semaglutide heart effects — specifically cardiac structure, gene expression in human heart tissue, and cardiovascular outcomes in people with diabetes and existing vascular or kidney disease. None of them changes how anyone takes the drug, but together they show where the research is heading.
Semaglutide Opioid Use Disorder Trial Opens Phase 2 Enrollment
A Phase 2 semaglutide opioid use disorder trial is now recruiting 200 adults in outpatient addiction treatment, testing whether the GLP-1 receptor agonist helps people refrain from illicit opioids. It is one of two new GLP-1 trials registered this week that push these drugs well outside diabetes and weight management.
Semaglutide Muscle Loss Study Joins New Trials on Lean Mass
Three separate research entries indexed in the past week — a longitudinal semaglutide muscle loss study, a review of skeletal muscle health during incretin-based therapy, and a newly posted Phase 4 trial — all converge on the same unanswered question. For anyone tracking a GLP-1 protocol, lean mass is moving from forum speculation to formal endpoint.
Retatrutide Cardiovascular Outcomes Trial Reaches Full Enrollment
The registry entry for TRIUMPH-Outcomes, the phase 3 retatrutide cardiovascular outcomes trial, was updated on August 24 to show the study active and closed to new participants. It is the largest single trial in Eli Lilly's retatrutide program and the one that will decide whether the triple agonist can claim organ-protection benefits rather than weight loss alone.
GLP-1 Non-Responders: New Review Asks If Response Can Be Predicted
A review indexed this month in Diabetes, Obesity & Metabolism takes on one of the least discussed features of incretin therapy: the substantial minority of people who get far less from it than trial averages suggest. Alongside new subgroup work on tirzepatide in women with polycystic ovary syndrome and a paper on muscle mass during incretin-based weight loss, the question of what separates GLP-1 non-responders from responders is moving from anecdote to research agenda.
Semaglutide cognitive side effects: 13,007-patient BMJ study
Three peer-reviewed papers examining semaglutide cognitive side effects and broader neuropsychiatric signals from GLP-1 receptor agonists were indexed within days of each other. The largest is a retrospective cohort of 13,007 people in the United States who already carried a psychiatric diagnosis.
Retatrutide Phase 3 Trial Completed in 2,335-Person Obesity Study
A ClinicalTrials.gov record updated August 21, 2026 shows Eli Lilly's largest registered retatrutide phase 3 trial completed after enrolling 2,335 participants with obesity or overweight. No outcome data has been posted to the registry yet, and retatrutide remains an investigational drug with no marketing approval anywhere.
Once-Monthly Semaglutide Depot Begins Phase 1/2a Human Trial
A registry entry posted this week describes a Phase 1/2a study of a once-monthly semaglutide depot in adults with type 2 diabetes. If the formulation holds up in later trials, it would change the interval that millions of people currently build their GLP-1 protocols around.
Oral Semaglutide Weight Loss Trial Opens With Lower-Dose Focus
A new Phase 3 oral semaglutide weight loss trial appeared on ClinicalTrials.gov this week with 450 planned participants and a stated goal of identifying a lower tablet dose. Two other oral semaglutide studies — one in East Asian adults with obesity, one testing a reformulated tablet in Japan — are now listed as completed.
Retatrutide Cardiovascular Risk Biomarkers Improve in New Analysis
Researchers reporting in Diabetes, Obesity & Metabolism describe improvements in retatrutide cardiovascular risk biomarkers in adults with obesity, with and without type 2 diabetes. It is the kind of result that shapes expectations for a drug still years from any approval — and it is not the same thing as an outcomes trial.
GLP-1 Gastroparesis Reviewed as Aspiration Questions Persist
Two new publications tackle the same underlying problem from different ends: a PLOS One systematic review of GLP-1 gastroparesis cases, and an Anaesthesia letter on gastric contents and aspiration risk after semaglutide cessation. Both matter to anyone on an incretin drug who has a procedure coming up.
Tirzepatide Combination Therapy Trials: Four New Add-On Studies
Registry records posted in the second week of August 2026 show a cluster of tirzepatide combination therapy trials and semaglutide add-on studies, where the approved drug is the floor and the experimental agent has to prove it adds something. One Roche study even withdraws tirzepatide partway through to see what holds.
Semaglutide Alcohol Use Disorder Trial Enrolls 622 Veterans
The largest test yet of a GLP-1 receptor agonist for drinking has opened enrollment: a VA-sponsored semaglutide alcohol use disorder trial seeking 622 participants. It follows a smaller federally funded phase 2 study and observational reports on smoking and mood in another patient population.